These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28315463)

  • 1. In vitro biphasic dissolution tests and their suitability for establishing in vitro-in vivo correlations: A historical review.
    Pestieau A; Evrard B
    Eur J Pharm Sci; 2017 May; 102():203-219. PubMed ID: 28315463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
    Tsume Y; Igawa N; Drelich AJ; Amidon GE; Amidon GL
    J Pharm Sci; 2018 Jan; 107(1):307-316. PubMed ID: 28919384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCS class IV drugs: Highly notorious candidates for formulation development.
    Ghadi R; Dand N
    J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
    Tsume Y; Matsui K; Searls AL; Takeuchi S; Amidon GE; Sun D; Amidon GL
    Eur J Pharm Sci; 2017 May; 102():126-139. PubMed ID: 28263914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems.
    Phillips DJ; Pygall SR; Cooper VB; Mann JC
    J Pharm Pharmacol; 2012 Nov; 64(11):1549-59. PubMed ID: 23058042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selection of a discriminant and biorelevant in vitro dissolution test for the development of fenofibrate self-emulsifying lipid-based formulations.
    Pestieau A; Krier F; Brouwers A; Streel B; Evrard B
    Eur J Pharm Sci; 2016 Sep; 92():212-9. PubMed ID: 27169683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a biphasic in vitro dissolution test for estimating the bioavailability of carbamazepine polymorphic forms.
    Deng J; Staufenbiel S; Bodmeier R
    Eur J Pharm Sci; 2017 Jul; 105():64-70. PubMed ID: 28487146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.
    Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S
    Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U; Sommer F; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a discriminative biphasic in vitro dissolution test and correlation with in vivo pharmacokinetic studies for differently formulated racecadotril granules.
    Deng J; Staufenbiel S; Hao S; Wang B; Dashevskiy A; Bodmeier R
    J Control Release; 2017 Jun; 255():202-209. PubMed ID: 28450206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug dissolution: significance of physicochemical properties and physiological conditions.
    Jambhekar SS; Breen PJ
    Drug Discov Today; 2013 Dec; 18(23-24):1173-84. PubMed ID: 24042023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation.
    Yang SG
    Arch Pharm Res; 2010 Nov; 33(11):1835-42. PubMed ID: 21116787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.